Agazisiran Drug Asset Due Diligence Report 2026

This Agazisiran Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Agazisiran can convert its siRNA profile and CFB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Agazisiran (query alias: Agazisiran)
Modality / target	siRNA; CFB; CFB modulators, RNAi
Highest global status	Phase 2
Originator	ADARx Pharmaceuticals, Inc.
Active developers	ADARx Pharmaceuticals, Inc., Tenacia Biotechnology (Shanghai) Co. Ltd.

The MCP disease footprint includes glomerulonephritis chronic complement component 3 glomerulopathy, Age Related Macular Degeneration, Geographic Atrophy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07522099	Phase 2	Recruiting	30	Primary endpoint not disclosed in English source
NCT06990269	Phase 2	Recruiting	240	Primary endpoint not disclosed in English source
NCT06989359	Phase 2	Recruiting	45	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EFFICACY AND SAFETY OF SI-RNA WITH NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS

Not Applicable; n=563; evaluation: Positive. Reported fields: HBeAg(follow-up): MD = -0.02, P-Value = 0.91; HBeAg(follow-up): MD = -0.02, P-Value = 0.91

Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)

Phase 1; n=41; evaluation: Positive. Reported fields: AE = The most common AE was upper respiratory tract infection, similar to placebo. There were no encapsulated bacterial infections nor clinically relevant changes in clinical lab tests, PE or vital signs. ; AE = The most common AE was upper respiratory tract infection, similar to placebo. There were no encapsulated bacterial infections nor clinically relevant changes in clinical lab tests, PE or vital signs.

Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial.

Phase 1; n=15; evaluation: Not stated in English source. Reported fields: AE = Most common treatment-related AEs: fatigue (47%), fever/chills (33%), allergic (33%), constipation (33%), nausea/vomiting (20%), all g1-2. 1 pt had g3 anemia and 2 pts had g2 thrombocytopenia, all shortly after CALAA-01 infusions with rapid recovery. 1 pt had possibly-related sinus bradycardia (g2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Agazisiran addresses glomerulonephritis chronic complement component 3 glomerulopathy, Age Related Macular Degeneration, Geographic Atrophy. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “target-level comparable: CFB.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CFB records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-22	Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds	NDA/BLA	US$1,461.0M stated total
2023-08-01	Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint	Phase 2	US$75.0M upfront; US$684.0M milestones; US$759.0M stated total
2010-03-30	GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases	Phase 2	US$35.0M upfront; US$1,500.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO